EGFR and colorectal carcinoma: EGFR signaling is the main mechanism in CRC resistance to KRASG12C inhibitors, that is, the combined blockade of EGFR and KRASG12C signaling can effectively inhibit tumors in CRC-derived organoids and xenografts [138].